Participating Faculty: Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus

Published Online: January 25, 2014
This supplement to The American Journal of Managed Care reports the results of 2 studies evaluating quality measure attainment in type 2 diabetes mellitus (T2DM). The first study evaluates the potential financial implications of quality measure attainment in patients with T2DM. The second study reports a post hoc analysis of a randomized controlled clinical trial evaluating the quality measure attainment of patients treated with either canagliflozin 300 mg/day or sitagliptin 100 mg/day in addition to metformin and sulfonylurea. Although further research is necessary, these results may help managed care organizations evaluate the value of improving quality measures associated with T2DM.
This supplement was supported by Janssen Pharmaceuticals, Inc.

The contents of this supplement represent the work of the authors.

The contents of this supplement may include information regarding the use of products that may be inconsistent with, or outside of, the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

Faculty



Robert A. Bailey, MD
Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey


Lawrence Blonde, MD
Director
Ochsner Diabetes Clinical Research Unit
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana


C. V. Damaraju, PhD
Director
Medical Affairs, Biostatistics
Janssen Research & Development, LLC
Raritan, New Jersey


Mei Sheng Duh, MPH, ScD
Managing Principal
Analysis Group, Inc
Boston, Massachusetts


Lawrence Garber, MD
Medical Director for Informatics
Reliant Medical Group
Worcester, Massachusetts


Jonathan Gravel, MSc
Economist
Groupe d’Analyse, Ltée
Analysis Group, Inc
Montreal, Quebec, Canada


Amanda M. Grittner, MA
Economist
Groupe d’Analyse, Ltée
Analysis Group, Inc
Montreal, Quebec, Canada


Marie-Hélène Lafeuille, MA
Senior Economist
Groupe d’Analyse, Ltée
Analysis Group, Inc
Montreal, Quebec, Canada

Patrick Lefebvre, MA
Vice President
Groupe d’Analyse, Ltée
Analysis Group, Inc
Montreal, Quebec, Canada


Silas C. Martin, MS
Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey


Gary E. Meininger, MD
Vice President, Franchise Medical Leader
Janssen Research & Development, LLC
Raritan, New Jersey


Marcia F. T. Rupnow, PhD
Senior Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey


Faculty Disclosures

These faculty report relationships with the following organizations:


Robert A. Bailey, MD
Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Stock ownership: Johnson & Johnson


Lawrence Blonde, MD
Grant/research support: Eli Lilly and Company; Novo Nordisk; Sanofi
Consultant: Amylin Pharmaceuticals, Inc; Eisai; GlaxoSmithKline; Janssen Pharmaceuticals, Inc; Merck & Co, Inc; Novo Nordisk; Pfizer; Sanofi; Santarus
Lecture fees: Amylin Pharmaceuticals, Inc; Bristol-Myers Squibb/AstraZeneca; Janssen Pharmaceuticals, Inc;Johnson & Johnson Diabetes Institute, LLC; Merck & Co, Inc; Novo Nordisk; Sanofi; Santarus; , Inc


C. V. Damaraju, PhD
Employment/stock ownership: Janssen Research & Development, LLC


Mei Sheng Duh, MPH, ScD
Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)


Jonathan Gravel, MSc
Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)


Amanda M. Grittner, MA
Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)


Marie-Hélène Lafeuille, MA
Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)


Patrick Lefebvre, MA
Employment: Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)


Silas C. Martin, MS
Employment: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Stock ownership: Johnson & Johnson


Gary E. Meininger, MD
Employment: Janssen Research & Development, LLC
Stock ownership: Johnson & Johnson, Merck & Co, Inc


Marcia F. T. Rupnow, PhD
Employment and meeting/conference attendance: Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Stock ownership: Johnson & Johnson

 
Lawrence Garber, MD, reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.


Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.
PDF
Feature
Recommended Articles
The announced price for alirocumab, the first PCSK9 inhibitor approved for use in the US, was the top story in managed care this week. Also, HHS announced $100 million available to combat substance abuse, and Medicare and Medicaid turn 50 years old.
Congressman Frank Pallone, Jr (D-NJ), explains the purpose of the National Institutes of Health Innovation Fund, which allows the organization to find cures for diseases that don’t have 1 yet.
Proposed mergers of Aetna and Humana, and Anthem and Cigna, raise questions of whether consumers will continue to see competition in health insurance markets.
Fifty years ago today, President Lyndon B. Johnson signed the law that created Medicare and Medicaid, setting in motion not only the greatest change in healthcare in the nation's history at that point, but also a lasting change for society.
Officials say the number of enrollees and their relative good health made it possible to negotiate lower rate increases. However, premium increases are higher in Northern California, where there is less competition.